At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 429 enrolled
Drug / intervention
Mometasone furoate nasal spray +1 moredrug
Likely dose
Mometasone furoate nasal spray 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Mometasone furoate nasal spray and Placebo for Seasonal Allergic Rhinitis. Completed, enrolled 429 participants.
Detailed Summary
This study is designed to assess the effectiveness of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMay 2007
Primary CompletionJul 2007
TodayJul 2026
First PostedMay 2, 2007
Enrollment StartMar 1, 2007
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 19.2 years ago
Interventions
Mometasone furoate nasal spraydrug
Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
Placebodrug
Two sprays in each nostril in the morning